Dupilumab‐related ocular surface disorders in a paediatric cohort with atopic dermatitis, treated in a tertiary paediatric hospital in London

Dupilumab‐related ocular surface disorders in a paediatric cohort with atopic dermatitis, treated in a tertiary paediatric hospital in London

Abstract Background Dupilumab is the first human monoclonal antibody approved for the treatment of moderate–severe atopic dermatitis (AD) in children from 6 years of age. Real‐world studies reviewing dupilumab‐related ocular surface disorders (DROSD) in the paediatric population are needed to detail...

Full description

Saved in:
Bibliographic Details
Main Authors: Anjali Rampersad, Karolina Gholam, Lea Solman, Natalia Cartledge, Sri Gore, Gabriela Petrof
Format: Article
Language:English
Published: Wiley 2024-12-01
Series:JEADV Clinical Practice
Subjects:
atopic dermatitis
biologics
eczema
ophthalmology
paediatrics
Online Access:https://doi.org/10.1002/jvc2.528
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/jvc2.528

Similar Items